论文部分内容阅读
为了评价帕诺洛司琼联合地塞米松预防顺铂化疗所致恶心和呕吐的疗效和安全性,在81例患者接受顺铂化疗中使用帕诺洛司琼和地塞米松预防恶心和呕吐,观察急性和延迟性无呕吐率、恶心程度、安全性以及多程化疗中的无呕吐率。81例患者共接受了247个周期的帕诺洛司琼和地塞米松的止呕治疗。在第1个周期中,无恶心率为28.4%(23/81),急性和延迟性无呕吐率分别为46.9%(38/81)和76.5%(62/81),主要不良反应为便秘(25.9%)、呃逆(23.4%)、乏力(13.6%)和头晕(11.1%)。第1～6个周期的无呕吐率分别为45.7%(37/81),36.1%(22/61),32.6%(15/46),27.3%(9/33),23.1%(3/13)和23.1%(3/13)。初步研究结果提示,帕诺洛司琼联合地塞米松安全有效地预防顺铂化疗中的恶心和呕吐,但疗效在多程化疗中不能很好地维持。
To evaluate the efficacy and safety of the combination of ranibizon and dexamethasone in the prevention of cisplatin-induced nausea and vomiting, propranonosetron and dexamethasone were used to prevent nausea and vomiting in 81 patients receiving cisplatin, Acute and delayed vomiting without vomiting, nausea, safety, and vomiting without multistep chemotherapy were observed. 81 patients received a total of 247 cycles of palonosetron and dexamethasone antiemetic treatment. In the first cycle, the rate of nausea was 28.4% (23/81), the rates of acute and delayed vomiting were 46.9% (38/81) and 76.5% (62/81), respectively. The main adverse reactions were constipation 25.9%), hiccups (23.4%), weakness (13.6%) and dizziness (11.1%). The vomiting rates in the first to sixth cycles were 45.7% (37/81), 36.1% (22/61), 32.6% (15/46), 27.3% (9/33), 23.1% (3/13) ) And 23.1% (3/13). Preliminary results suggest that, in combination with dexamethasone, palonosetron is safe and effective in preventing nausea and vomiting in cisplatin chemotherapy, but the effect is not well maintained in multistep chemotherapy.